Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia
about
siRNA Versus miRNA as Therapeutics for Gene SilencingMicroRNAs as potential therapeutics for treating spinal cord injury.Alterations in the mir-15a/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL)T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.MicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders.In vivo delivery of miRNAs for cancer therapy: challenges and strategies.MicroRNAs as therapeutic targets in chemoresistance.Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus.MicroRNA Therapeutics: the Next Magic Bullet?Non-coding RNAs in cancer brain metastasis.MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases.Altering β-cell number through stable alteration of miR-21 and miR-34a expression.Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.Effect of high sugar levels on miRNA expression. Studies with galactosemic mice lenses.miR‑15a represses cancer cell migration and invasion under conditions of hypoxia by targeting and downregulating Bcl‑2 expression in human osteosarcoma cells.
P2860
Q26786876-1F19082F-B4D9-4DBD-B9F3-8170ED60B20BQ35020885-24095C25-E1EE-4E84-B6E4-3457F27A3A57Q35951131-22E5919F-C4EA-4AC8-98E7-C1B5A3E4AD12Q36245171-FDA2D018-181A-43BB-B813-C9CB6BC0C3DDQ36422143-17C214DE-A8BF-458E-8DDB-ACB62DFCFB87Q37228217-70EB1A49-9432-427D-8C76-9FEDF298B525Q37381107-E48A569A-6FF8-453F-A426-B501E061FD4EQ37398927-8A0C26E6-D9F7-467A-A934-74F0980A041BQ38390631-6FEC80B6-EB43-46DA-B2CA-3E94D4281ADEQ38681238-535806BE-935F-4498-9CE2-94B6FA5AC159Q38795034-87199228-3057-4815-876E-32C4042103A2Q38931231-F374BB98-C7E7-4688-B44A-D5EE89C7B56BQ39039713-0023041F-0BBE-44FF-B429-FBC751035B22Q39101593-CF6E65BB-5AF1-49C1-8263-C1FE728BADCCQ39181050-B5B9EEC1-8051-4381-95E2-AA9C84F0C78CQ41977764-1E688B19-280F-4278-8417-E828ADECF1A0Q52683999-D5E52218-ECF0-4217-97EF-C2EE2B448C81
P2860
Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Systemic in vivo lentiviral de ...... f chronic lymphocytic leukemia
@en
Systemic in vivo lentiviral de ...... f chronic lymphocytic leukemia
@nl
type
label
Systemic in vivo lentiviral de ...... f chronic lymphocytic leukemia
@en
Systemic in vivo lentiviral de ...... f chronic lymphocytic leukemia
@nl
prefLabel
Systemic in vivo lentiviral de ...... f chronic lymphocytic leukemia
@en
Systemic in vivo lentiviral de ...... f chronic lymphocytic leukemia
@nl
P2093
P2860
P356
P1433
P1476
Systemic in vivo lentiviral de ...... f chronic lymphocytic leukemia
@en
P2093
C Underbayev
D Vollenweider
F Mazzella
H Fernandes
M F Laurindo
P2860
P2888
P304
P356
10.1038/GENE.2011.58
P577
2011-09-01T00:00:00Z